Skip to main content

Viewing r2 — May 14, 2026 — CURRENT

Back to History

Interactions, related substances, and reports reflect the current entry and are not shown for historical revisions.

Coca (Erythroxylum coca Lam., Erythroxylaceae) is a flowering shrub native to the Andes whose leaves contain the stimulant alkaloid cocaine. Cocaine determines the pharmacological character of every coca preparation. It blocks the brain's dopamine recycling system, flooding reward circuits and producing the plant's stimulant and euphoric effects.[1]

Open Beta

Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.

FamilyErythroxylaceae
GenusErythroxylum
SpeciesErythroxylum coca Lam.
Native rangeWestern South America — Bolivia, Brazil (North), Colombia, Ecuador, Peru
CultivationExclusively cultivated; major producing regions Colombia (~253,000 ha), Peru (~93,000 ha), Bolivia (~31,000 ha). Two varieties: var. coca (Bolivian/Huánuco, eastern Andes montane forest) and var. ipadu (Amazonian lowlands, lower alkaloid content).
→ COCAINE0.11–0.96 %
coca leaf chewing (with alkaline additive)coca tea (mate de coca)cocaine hydrochloride (intranasal)smoked cocaine (freebase / crack)intravenous cocaine
common20–60 g (fresh leaf)
~2–40 mg cocaine per session depending on leaf mass, alkaloid content, and alkaline additive
Fresh or dried leaves chewed with calcium hydroxide, sodium bicarbonate, or llipta (plant ash). Alkaline pH converts cocaine to freebase form for buccal absorption. Drug accumulation from repeated chewing is unlikely given slow absorption rate. Bioavailability variable and low.
common1–2 g (dried leaf)
~2–5 mg cocaine per cup
Hot water infusion steeped 5–15 minutes. Oral bioavailability ~32–45% with significant first-pass metabolism. Legal and widely consumed in Bolivia, Peru, and parts of Argentina. Will produce positive urine drug tests for benzoylecgonine.
threshold5–10 mg
common20–75 mg
heavy100+ mg
~60–75% bioavailability
Insufflation of cocaine HCl powder. Chronic use causes rhinitis, septal perforation, palatal perforation, and saddle nose deformity via ischemia from vasoconstriction.
common50–200 mg
~70–80% bioavailability
Cocaine HCl converted to freebase with baking soda or solvent extraction. Pyrolysis produces anhydroecgonine methyl ester (AEME), a biomarker specific to smoked route. Fastest non-IV onset; strongest compulsive redosing drive. Pulmonary toxicity including crack lung syndrome specific to this route.
common0.2–1 mg/kg
100% bioavailability
Highest risk of acute cardiovascular events. Introduces injection-related infection risks (HIV, HCV, bacterial endocarditis). Street use doses highly variable. Controlled study dose range: 0.2–1.0 mg/kg.
Builduprapid
Cross-tol.amphetamines
Absolute6 entries
Pre-existing cardiac conditionsConcurrent beta-blocker therapyUncontrolled hypertensionHyperthyroidism / pheochromocytomaPregnancyPrenatal exposure
Relative4 entries
Schizophrenia spectrum / psychosis vulnerabilityLiver diseaseConcurrent MAOI useConcurrent tricyclic antidepressant use
Dosage varies by body weight, tolerance & metabolism · Not medical advice · Terms

Archaeological evidence places Andean coca use at least 8,000 years before present.[2] Cocaine was first isolated from the leaf in 1860, setting off a wave of pharmaceutical applications and eventually tight international restriction. Today both coca leaf and cocaine are scheduled under the 1961 UN Single Convention, though Bolivia and Peru maintain legal frameworks for traditional leaf use.[3]

Subjective effects include stimulation, euphoria, appetite suppression, increased confidence, and local numbness in the mouth and throat. The experience varies enormously by preparation: leaf chewing produces mild, sustained alertness comparable to strong tea, while smoked cocaine delivers a brief, overwhelming rush followed by rapid craving. Anxiety, paranoia, racing heart, and a dysphoric crash are characteristic unsought effects, particularly with refined preparations.

Cocaine carries significant abuse liability and cardiovascular toxicity — including risk of heart attack, arrhythmia, and sudden cardiac death.[4] The illicit supply is heavily contaminated: levamisole adulterates an estimated 69–80% of US cocaine, causing blood disorders independent of cocaine's own effects,[5] and fentanyl contamination is increasingly common. No approved treatment for cocaine use disorder exists as of 2026,[6] and controlled data on whole-leaf preparations remain sparse.

History[edit]

Traditional and historical use

Indigenous peoples of the Andes have cultivated and consumed coca for at least 8,000 years.[2] Traditional preparation involves placing fresh or dried leaves in the cheek alongside an alkaline additive — calcium hydroxide, plant ash, or sodium bicarbonate — which raises buccal pH and promotes cocaine absorption.[7] Documented uses include stamina during physical labor, hunger and fatigue suppression, altitude sickness relief, mild analgesia, and ceremonial purposes.[7][2]

Western discovery and pharmaceutical development

Albert Niemann first isolated cocaine from coca leaves in 1860 at the University of Göttingen, noting its anesthetic effect on his own tongue.[8] Carl Koller demonstrated cocaine as a topical anesthetic for eye surgery in 1884, transforming the field.[8] Coca-Cola launched in 1886 using coca extract; the product was decocainized by 1903.[7]

Modern era

The Harrison Narcotics Tax Act (1914) restricted non-medical cocaine in the United States. The 1961 UN Single Convention placed both coca leaf and cocaine on Schedule I — an unusual dual scheduling that explicitly controls the plant alongside its isolated alkaloid. In October 2025, the WHO Expert Committee completed a comprehensive review and recommended maintaining Schedule I classification, while acknowledging the low public health risk of traditional consumption and the cultural significance of coca to indigenous peoples.[3]

Botanical Overview[edit]

Coca belongs to the genus Erythroxylum and the family Erythroxylaceae — a small family of tropical and subtropical shrubs. Two primary cultivated species are recognized: E. coca (Huánuco coca) and E. novogranatense (Colombian coca). Each has varieties that differ in alkaloid content and geographic distribution.

Coca is native to the eastern Andean slopes of Peru and Bolivia, thriving in warm, humid montane forest between roughly 500 and 2,000 meters elevation. Bolivia, Peru, and Colombia account for virtually all current cultivation. The plant is not known to persist in the wild independent of human cultivation.

The shrub grows 1–3 meters tall with slender, oval leaves 4–8 cm long. Each leaf carries two faint lines running parallel to the central vein — a diagnostic feature distinguishing Erythroxylum from similar-looking shrubs. Small yellowish-white flowers produce red drupes approximately 1 cm in length.

Alkaloid Profile[edit]

Cocaine is the dominant active alkaloid in coca leaf, present at 0.2–1.0% of dry weight. It blocks the brain's dopamine, norepinephrine, and serotonin recycling systems simultaneously, with an additional local anesthetic effect produced by sodium channel blockade.[1][9] The pharmacological character of coca preparations is determined almost entirely by cocaine itself.

Several minor alkaloids are present but poorly understood. Cinnamoylcocaine and its isomers are structurally related to cocaine but pharmacologically weaker. Truxillines are dimeric cocaine derivatives present in trace amounts. Hygrine, a separate alkaloid class, lacks meaningful central nervous system activity. Traditional users sometimes attribute a qualitative difference between whole-leaf coca and purified cocaine to this full alkaloid matrix — but no controlled study has demonstrated that effect.

E. novogranatense tends toward lower cocaine content with a proportionally higher fraction of minor alkaloids than E. coca. Harvest season, soil conditions, altitude, and drying method all influence the final alkaloid profile of available leaf material.

Neuroscience[edit]

Where it acts

Cocaine's psychoactive effects arise from blocking dopamine recycling in the brain's mesolimbic mesolimbic pathway — the projection from the ventral tegmental area to the nucleus accumbens.[1] This floods synapses with dopamine, producing euphoria and reinforcing the behavior. Cocaine also blocks norepinephrine recycling, driving cardiovascular arousal and heightened alertness; sodium channel blockade produces the local anesthetic effect and creates arrhythmia risk.[9]

What it changes

Repeated cocaine use triggers synaptic changes in the reward pathway that drive compulsive use and increase relapse vulnerability.[2] Tolerance to euphoria develops rapidly, while sensitivity to psychomotor effects and psychosis risk increases — chronic users chase a diminishing high while facing escalating psychiatric danger. With prolonged use, cocaine also speeds up its own liver metabolism,[10] generating a more toxic byproduct called norcocaine.[11]

Subjective Effects[edit]

Summary

Coca preparations span a wide experiential range determined almost entirely by preparation method. Traditional leaf chewing produces subtle, sustained alertness with mild appetite suppression and gentle mouth numbness — qualitatively closer to a strong cup of tea than to the intense euphoria associated with refined cocaine. Smoked or injected cocaine delivers brief, overwhelming euphoria followed almost immediately by craving and the drive to redose.

In terms of stimulant intensity, coca leaf chewing sits somewhere between caffeine and low-dose amphetamine. Refined cocaine administered intranasally or by inhalation is closer to methamphetamine in reinforcement potency and addiction trajectory — though its effects are substantially shorter-lived and its cardiovascular risk profile is distinct.

Effect Grid

Dose Level:
Description

Clear stimulation and cognitive euphoria with pronounced confidence and sociability enhancement. Communication enhancement is evident — speech flows easily, talkativeness increases. Focus enhancement and thought acceleration are noticeable. Motivation enhancement drives purposeful activity. Ego inflation produces feelings of competence and grandiosity.

Appetite suppression is pronounced. Heart rate and blood pressure increase measurably. Pupil dilation is visible. Vasoconstriction produces nasal numbness (intranasal) and peripheral cooling. Restlessness and mild bruxism may emerge toward the end of the experience. Insomnia is likely if taken within several hours of intended sleep.

For intranasal cocaine HCl, common doses are 20-75 mg. Coca leaf chewing at 20-60 g with alkaline additive delivers approximately 10-30 mg cocaine. Compulsive redosing urge begins to emerge at this tier, particularly with faster routes of administration.

Modeled from the effect's dose-dependence curve — not per-substance measurements.

Perception(1)likelihood · intensity
Taste suppression
possible
Body(22)likelihood · intensity
Stimulation
likely
Vasoconstriction!
likely
Wakefulness
likely
Appetite suppression
possible
Pain suppression
possible
Tingling / electric sensations
possible
Dry mouth
possible
Heart rate perception changes
possible
Pupil dilation
possible

Tingling / electric sensations · Dry mouth · Heart rate perception changes · Pupil dilation · Body high · Insomnia · Muscle tension · Restlessness · Salivation · Motor control enhancement · Excessive sweating · Nausea · Nausea suppression · Respiratory stimulation · Sexual arousal enhancement · Bruxism · Vomiting

Body high · Insomnia · Muscle tension · Restlessness · Salivation · Motor control enhancement · Excessive sweating · Nausea · Nausea suppression · Respiratory stimulation · Sexual arousal enhancement · Bruxism · Vomiting

Thinking(11)likelihood · intensity
Cognitive euphoria
possible
Thought acceleration
possible
Focus enhancement
possible
Information processing enhancement
possible
Motivation enhancement
possible
Analysis enhancement
possible
Cognitive flexibility
possible
Compulsive redosing urge!
possible
Language enhancement
possible

Motivation enhancement · Analysis enhancement · Cognitive flexibility · Language enhancement · Memory enhancement · Creativity enhancement

Memory enhancement · Creativity enhancement

Feeling(4)likelihood · intensity
Euphoria
likely
Anxiety
possible
Irritability
possible
Paranoia!
rare
Self(7)likelihood · intensity
Craving
possible
Communication enhancement
possible
Disinhibition
possible
Sociability enhancement
possible
Social connection
possible
Ego inflation
possible
Flow state
possible

Ego inflation · Flow state

Time(1)likelihood · intensity
Time alteration
possible
Awareness(1)likelihood · intensity
Sustained attention (vicara)
likely
Likelihood: how common this effect is at the selected dose level.This effect has safety implications — review before use.

Timeline · by preparation

coca leaf chewing (with alkaline additive) (sublingual)
onset15 min – 45 min
peak1 h – 1.5 h
offset1.5 h – 4 h
coca tea (mate de coca) (oral)
onset30 min – 1 h
peak1 h – 1.5 h
offset1.5 h – 4 h
cocaine hydrochloride (intranasal) (intranasal)
onset3 min – 5 min
peak15 min – 30 min
offset45 min – 1.5 h
smoked cocaine (freebase / crack) (smoked)
onset0 s – 1 min
peak3 min – 5 min
offset10 min – 20 min
intravenous cocaine (intravenous)
onset0 s – 30 s
peak1 min – 2 min
offset20 min – 40 min

Safety[edit]

Harm
Acute toxicity
High
Chronic toxicity
Critical
Withdrawal
Moderate
Tolerance buildup
rapid
Tolerance reset
—
Dependence
Physical
Low
Psychological
High
Compulsive redosing
High
Dose escalation
Moderate
Cross-tol.
amphetamines
Risk Shape
TOXPHYPSYWDRREDTOL

Toxicity

Cocaine is the most frequent cause of drug-related death reported by US medical examiners.[12] The primary risk is cardiovascular: frequent users face a 7-fold higher risk of heart attack.[4][9][13] Cocaine narrows coronary arteries, promotes clot formation, and disrupts heart rhythm — any of which can cause sudden death.

Chronic use generates norcocaine, a liver-toxic byproduct that causes liver cell death and fatty change.[14] Multi-organ failure combining muscle breakdown, kidney injury, and liver damage is documented.[15]

Smoked cocaine can trigger "crack lung" — acute respiratory distress with fever, blood in the cough, and lung bleeding within 48 hours.[16] Both ischemic and hemorrhagic stroke are documented; reversible cerebral vasoconstriction has been reported even after coca tea at high altitude.[17]

Levamisole contaminates an estimated 69–80% of illicit US cocaine,[5][18] causing dangerously low white blood cell counts and blood vessel inflammation. Fentanyl contamination is increasingly common and introduces opioid overdose risk separate from cocaine's own toxicity.

Psychological Risks

Paranoid delusions, hallucinations, and thought disorganization can emerge with cocaine use. Prevalence reaches 86.5% in some clinical populations.[19] High cumulative dose, smoked or intravenous route, cannabis co-use, and pre-existing ADHD all increase the risk.[19] Repeated use does not build tolerance to psychosis — it progressively lowers the threshold for psychotic symptoms. Anxiety, panic, grandiosity, and impaired judgment occur across all preparations at sufficient doses.

Tolerance & Dependence

Tolerance to euphoria develops rapidly. Simultaneously, sensitivity to psychomotor effects and psychosis risk increases — the opposite of tolerance. Dependence is primarily psychological, driven by mesolimbic dopamine reinforcement, though physical dependence is also present. Withdrawal follows a three-phase pattern[20]:

  • Phase 1 — Crash (hours to 4 days): dysphoria, fatigue, hypersomnia with REM rebound effect, appetite enhancement, temporarily reduced craving.
  • Phase 2 — Withdrawal (1–10 weeks): anhedonia, anxiety, sleep disturbance, intense cue-triggered cravings; highest relapse risk period.
  • Phase 3 — Extinction (months to years): Gradual normalization; intermittent cue-triggered cravings persist.[20]
No FDA-approved pharmacotherapy for cocaine use disorder exists as of 2026.[6] Current evidence supports cognitive behavioral therapy, contingency management, and treatment of comorbid psychiatric conditions.

Recovery resources, crisis lines, and support pathways → View all

Cocaine-associated chest pain should be evaluated as potential myocardial infarction. Beta-blockers are contraindicated — unopposed alpha-adrenergic stimulation worsens vasoconstriction and hypertension. First-line management: benzodiazepines for agitation, nitroglycerin or calcium channel blockers for ischemia, phentolamine for refractory hypertension.

Drug Interactions

Ethanol (alcohol): The most clinically significant interaction. Liver enzymes convert cocaine and alcohol together into cocaethylene — more toxic than cocaine itself and longer-lasting.[21][22][23] Cocaethylene yield varies by route: oral (34%) > intravenous (24%) > smoked (18%).[21]

Beta-adrenergic blockers: Contraindicated. Blocking beta receptors leaves cocaine's arterial constriction effects unopposed, producing severe hypertension and coronary vasospasm.

MAO inhibitors: Risk of severe blood pressure crisis and serotonin overload via amplified monoamine activity.safety citation needed

CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir): May raise cocaine blood levels by slowing its clearance while reducing norcocaine formation.[11]safety citation needed

Tricyclic antidepressants: Additive cardiovascular toxicity from combined sodium channel blockade and norepinephrine buildup.safety citation needed

Contraindications

Pregnancy is an absolute contraindication — associated with placental abruption and fetal brain development effects.[24] Pre-existing cardiovascular disease is an absolute contraindication; the risk of heart attack and sudden death rises dramatically.[4] Concurrent beta-blocker therapy is absolutely contraindicated. Hepatic impairment, concurrent MAOI or tricyclic antidepressant therapy, and personal or family history of schizophrenia or psychosis are relative contraindications.[19]

Preparations[edit]

Coca leaf chewing (traditional)

Coca leaf chewing is the oldest and mildest preparation. Fresh or dried leaves (20–60 g per session) are held in the cheek with an alkaline additive — calcium hydroxide, sodium bicarbonate, or llipta (plant ash) — which raises buccal pH and promotes cocaine absorption.[7] Onset: 15–45 minutes. Peak: 60–90 minutes. Duration: 2–4 hours. Effects are mild sustained alertness, appetite suppression, and gentle analgesia. Accumulation from repeated chewing is unlikely given the slow absorption rate.[25]

Coca tea (mate de coca)

Coca tea is prepared by steeping dried leaves in hot water for 5–15 minutes. Onset: 30–60 minutes. Duration: 2–4 hours. Oral bioavailability is approximately 32–45%.[26] Effects are comparable to leaf chewing — mild stimulation and alertness. Legal and widely consumed in Bolivia, Peru, and parts of Argentina.

Cocaine hydrochloride (intranasal)

Intranasal cocaine (insufflation of cocaine hydrochloride powder) produces onset in 3–5 minutes, peak effects at 15–30 minutes, and duration of 45–90 minutes. Bioavailability is approximately 60–75%.[25] Effects are markedly more intense than leaf preparations: strong euphoria, heightened confidence, talkativeness, and a pronounced crash that drives redosing. Repeated use causes nasal mucosal damage.

Smoked cocaine (freebase / crack)

Smoked cocaine (freebase or crack) produces onset in under one minute. Peak: 3–5 minutes. Duration: 10–20 minutes. Bioavailability is approximately 70–80%. The extreme brevity of effects produces the strongest compulsive redosing drive of any non-intravenous preparation. Pulmonary toxicity, including "crack lung" syndrome, is specific to this route.[16]

Intravenous cocaine

Intravenous cocaine produces onset within seconds, peaks at 1–2 minutes, and lasts 20–40 minutes with 100% bioavailability. This route carries the highest risk of acute cardiovascular events and introduces infection risk from injection practices. Compulsive redosing frequency is comparable to smoked cocaine.

Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.

Harm Reduction[edit]

Forms & Identification

Reagent ResultsNot recorded+ add reagent results
AppearanceNot recorded+ add appearance
Red FlagsNot recorded+ add red flags

Lab testing is the only reliable way to determine the purity of refined cocaine. The illicit supply is extensively adulterated — levamisole contaminates the majority of US cocaine, and fentanyl is increasingly present. Fentanyl test strips detect fentanyl but not all synthetic opioid analogs. Reagent testing (Scott/cobalt thiocyanate) confirms cocaine is present but cannot quantify purity or identify all adulterants.

For coca leaf products purchased in Andean countries, adulterant risk is substantially lower, but standardized potency testing is not available. Alkaloid content varies across batches and cultivars — dose conservatively when switching sources.

Guidelines

  • Start with the lowest effective amount and wait for full onset before considering redosing — onset varies dramatically by preparation (leaf chewing: 15–45 min; intranasal: 3–5 min)
  • Pre-measure amounts before a session to limit compulsive redosing; the rapid offset of smoked and intranasal cocaine drives repeated use
  • Test all refined cocaine products with fentanyl test strips before use
  • Use in the presence of others who can recognize and respond to medical emergencies
  • Stay hydrated and eat before use — cocaine suppresses appetite and masks dehydration
  • Monitor heart rate; stop immediately and seek medical attention if chest pain, palpitations, or difficulty breathing occur
  • Alternate nostrils and rinse with saline after intranasal use to reduce mucosal damage
  • Avoid binge patterns; set a firm time limit for sessions

Set & Setting

The setting significantly influences risk. Social environments that normalize compulsive redosing — common with intranasal and smoked preparations — amplify dependence risk. Using alone increases the danger of unwitnessed cardiac events or psychotic episodes.

A sober companion who can recognize cardiac distress or psychotic symptoms and call emergency services reduces acute mortality risk. For traditional coca leaf preparations, risk is substantially lower but not zero — reversible cerebral vasoconstriction has been reported with coca tea at high altitude.

Aftercare & integration. The post-cocaine crash brings dysphoria, fatigue, and appetite enhancement. For intranasal and smoked preparations, the crash can begin within minutes of last use and persist for hours to days depending on session length and cumulative dose.

Prioritize sleep, hydration, and nutrition during the crash period. Hypersomnia is expected and should not be resisted. Avoid using other stimulants to counteract post-cocaine fatigue — this extends recovery time and increases cardiovascular strain. For regular users, the withdrawal period (1–10 weeks) involves anhedonia, anxiety, and intense cue-triggered cravings. Identifying and avoiding environmental cues associated with prior use reduces relapse risk during this vulnerable window.

Recovery & Support

No FDA-approved pharmacotherapy for cocaine use disorder exists as of 2026. Evidence-supported treatments include cognitive behavioral therapy (CBT), contingency management (CM), and integrated treatment of comorbid psychiatric conditions.

For individuals seeking to reduce or stop cocaine use:

  • SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7 referral service)
  • Cocaine Anonymous: peer-support fellowship modeled on the 12-step framework
  • Outpatient CBT and contingency management programs are available through most addiction treatment centers

Abrupt cessation of cocaine is medically safe, though psychologically difficult. The highest relapse risk occurs during weeks 1–10 after last use, when cue-triggered cravings are most intense. Professional support during this period significantly improves outcomes.

Recovery resources, crisis lines, and support pathways → View all

Emergency Response

Recognizing an emergency:

Immediate steps:

  • 1. Call emergency services (911 or local emergency number) immediately if any of the above are present
  • 2. Keep the person calm and in a cool, quiet environment
  • 3. If conscious, position sitting upright to ease breathing
  • 4. If unconscious and breathing, place in recovery position
  • 5. If not breathing, begin CPR
  • 6. Do not administer beta-blockers — they worsen cocaine-related cardiac events

What to tell the dispatcher: Name the substance (cocaine or coca preparation), estimated amount and time of last use, and current symptoms. Good Samaritan laws in many jurisdictions provide legal protection for reporting drug-related emergencies.

Reversal agents: No specific reversal agent for cocaine toxicity exists. If fentanyl contamination is suspected and opioid overdose signs are present (slowed or stopped breathing, pinpoint pupils, blue lips), administer naloxone immediately.

references

  1. [1] 
    ^abcHeal DJ, Gosden J, Smith SL (2014) Dopamine reuptake transporter (DAT) 'inverse agonism' — a novel hypothesis to explain the enigmatic pharmacology of cocaine — Neuropharmacology doi:10.1016/j.neuropharm.2014.06.012
  2. [2] 
    ^abcdRestrepo DA, Saenz E, Jara-Muñoz OA, Calixto-Botía IF, Rodríguez-Suárez S, Zuleta P, Chavez BG, Sanchez JA, D'Auria JC (2019) Erythroxylum in Focus: An Interdisciplinary Review of an Overlooked Genus — Molecules doi:10.3390/molecules24203788
  3. [3] 
    ^abWorld Health Organization (2025) WHO Expert Committee concludes critical review of coca leaf, recommends maintaining current controls (December 2025) Link
  4. [4] 
    ^abcLucyk SN (2022) Acute Cardiovascular Toxicity of Cocaine — The Canadian Journal of Cardiology doi:10.1016/j.cjca.2022.05.003
  5. [5] 
    ^abBuchanan JA, Lavonas EJ (2012) Agranulocytosis and other consequences due to use of illicit cocaine contaminated with levamisole — Current Opinion in Hematology doi:10.1097/moh.0b013e32834da9ef
  6. [6] 
    ^abSinclair JM, Kalk NJ, Kaar SJ, et al. (2026) Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology — Journal of psychopharmacology doi:10.1177/02698811251399593